Publications by authors named "Maria Sergeeva"

Claim this Profile
A
A highly divergent sample from a nearly extinct SARS-CoV-2 lineage in a patient with long-term COVID-19.
Elena Nabieva, Galya V Klink, Andrey B Komissarov, Stanislav V Zaitsev, Maria Sergeeva

Front Cell Infect Microbiol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Persistence of Cross-Reactive Immunity to Influenza B/Yamagata Neuraminidase Despite the Disappearance of the Lineage: Structural and Serological Evidence.
Yulia Desheva, Polina Kudar, Maria Sergeeva, Pei-Fong Wong, Tamara Shvedova

Int J Mol Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide fibrils as a vaccine: Proof of concept.
Yana Zabrodskaya, Konstantin Sivak, Maria Sergeeva, Andrey Aleksandrov, Elena Kalinina

J Immunol Methods· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuraminidase Antibody Response to Homologous and Drifted Influenza A Viruses After Immunization with Seasonal Influenza Vaccines.
Yulia Desheva, Maria Sergeeva, Polina Kudar, Andrey Rekstin, Ekaterina Romanovskaya-Romanko

Vaccines (Basel)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A potent, broadly neutralizing human monoclonal antibody that efficiently protects hACE2-transgenic mice from infection with the Wuhan, BA.5, and XBB.1.5 SARS-CoV-2 variants.
Sergey V Guselnikov, Konstantin O Baranov, Sergey V Kulemzin, Tatyana N Belovezhets, Anton N Chikaev, Maria V Sergeeva

Front Immunol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of interferon-λ and receptor expression in response to in vitro respiratory viral infection.
Alexey A Lozhkov, Nikita D Yolshin, Irina L Baranovskaya, Marina A Plotnikova, Maria V Sergeeva

Acta Virol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine.
Larisa V Kordyukova, Andrey V Moiseenko, Marina V Serebryakova, Marina A Shuklina, Maria V Sergeeva

Viruses· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 escape from cytotoxic T cells during long-term COVID-19.
Oksana V Stanevich, Evgeniia I Alekseeva, Maria Sergeeva, Artem V Fadeev, Kseniya S Komissarova

Nat Commun· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up.
Berik Khairullin, Kunsulu Zakarya, Mukhit Orynbayev, Yergali Abduraimov, Markhabat Kassenov, Maria Sergeeva

EClinicalMedicine· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages.
Sergey V Kulemzin, Maria V Sergeeva, Konstantin O Baranov, Andrey A Gorchakov, Sergey V Guselnikov

J Pers Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hybrid Proteins with Short Conformational Epitopes of the Receptor-Binding Domain of SARS-CoV-2 Spike Protein Promote Production of Virus-Neutralizing Antibodies When Used for Immunization.
Anna S Karyagina, Alexander V Gromov, Tatyana M Grunina, Alexander M Lyaschuk, Maria S Poponova, Maria V Sergeeva

Biochemistry (Mosc)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan.
Kunsulu Zakarya, Lespek Kutumbetov, Mukhit Orynbayev, Yergali Abduraimov, Kulyaisan Sultankulova, Maria Sergeeva

EClinicalMedicine· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal Immunization with the Influenza A Virus Encoding Truncated NS1 Protein Protects Mice from Heterologous Challenge by Restraining the Inflammatory Response in the Lungs.
Kirill Vasilyev, Anna-Polina Shurygina, Maria Sergeeva, Marina Stukova, Andrej Egorov

Microorganisms· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid spread of influenza A(H1N1)pdm09 viruses with a new set of specific mutations in the internal genes in the beginning of 2015/2016 epidemic season in Moscow and Saint Petersburg (Russian Federation).
Andrey Komissarov, Artem Fadeev, Maria Sergeeva, Sergey Petrov, Kseniya Sintsova

Influenza Other Respir Viruses· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines.
Sabine Nakowitsch, Andrea M Waltenberger, Nina Wressnigg, Nicole Ferstl, Andrea Triendl, Maria Sergeeva

Biotechnol J· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans.
Abylay R Sansyzbay, Marianna K Erofeeva, Berik M Khairullin, Nurlan T Sandybayev, Zhailaubay K Kydyrbayev, Maria V Sergeeva

Clin Vaccine Immunol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass spectrometry and biochemical analysis of RNA polymerase II: targeting by protein phosphatase-1.
Marina Jerebtsova, Sergei A Klotchenko, Tatiana O Artamonova, Tatiana Ammosova, Kareem Washington, Maria V Sergeeva

Mol Cell Biochem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
David A Ellis, Julie K Blazel, Chinh V Tran, Frank Ruebsam, Douglas E Murphy, Maria V Sergeeva

Bioorg Med Chem Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of tricyclic 5,6-dihydro-1H-pyridin-2-ones as novel, potent, and orally bioavailable inhibitors of HCV NS5B polymerase.
Frank Ruebsam, Douglas E Murphy, Chinh V Tran, Lian-Sheng Li, Jingjing Zhao, Maria V Sergeeva

Bioorg Med Chem Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
Frank Ruebsam, Chinh V Tran, Lian-Sheng Li, Sun Hee Kim, Alan X Xiang, Maria V Sergeeva

Bioorg Med Chem Lett· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.
Peter S Dragovich, Julie K Blazel, David A Ellis, Qing Han, Ruhi Kamran, Maria V Sergeeva

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
Frank Ruebsam, Zhongxiang Sun, Benjamin K Ayida, Stephen E Webber, Yuefen Zhou, Maria V Sergeeva

Bioorg Med Chem Lett· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.
David A Ellis, Julie K Blazel, Stephen E Webber, Chinh V Tran, Peter S Dragovich, Maria V Sergeeva

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.
Sun Hee Kim, Martin T Tran, Frank Ruebsam, Alan X Xiang, Benjamin Ayida, Maria V Sergeeva

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
Frank Ruebsam, Stephen E Webber, Martin T Tran, Chinh V Tran, Douglas E Murphy, Maria V Sergeeva

Bioorg Med Chem Lett· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis